Ljungman Lab
The Ljungman Lab has developed the nascent RNA Bru-seq techniques for profiling of transcription and RNA processing and the KLIPP approach for precision targeting of cancer with CRISPR
Explore the Ljungman Lab
The Ljungman Lab at the University of Michigan is dedicated to understanding and manipulating gene expression in cancer and normal cells through cutting-edge genomic and therapeutic approaches.
As a long-standing member of the ENCODE Consortium, the lab developed and applied advanced transcriptomic techniques like Bru-seq to map transcriptional activity, splicing dynamics and RNA stability across diverse cell types. They are now participating in the GENCODE Consortium to advance the annotation of the human genome.
Additionally, the Ljungman Lab is pioneering a novel CRISPR-based cancer therapy, KLIPP, which precisely targets cancer-specific chromosomal rearrangements using genome sequencing data and lipid nanoparticle delivery systems. These integrated efforts aim to develop safe and personalized precision therapies for cancer.
Join Us
Please contact Mats Ljungman, PhD ([email protected]) if you are interested in working with the Ljungman Lab.
Mats E Ljungman, PhD
Professor of Radiation Oncology, Medical School
Professor of Environmental Health Sciences, School of Public Health
